MOR103

BIOLOGICAL2 trials

Sponsors

MorphoSys AG

Conditions

Multiple SclerosisRheumatoid Arthritis

Phase 1

Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

CompletedNCT01023256

MorphoSys AGRheumatoid Arthritis

Start: 2009-12-31End: 2012-06-30Updated: 2014-10-24

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

CompletedNCT01517282

MorphoSys AGMultiple Sclerosis

Start: 2012-01-31End: 2014-02-28Updated: 2014-11-21

Related Papers

Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.

2015-05-2184 citations

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

2014-02-17120 citations